Key insights
- The author expresses concern over Novo Nordisk's (NVO) recent price decline to its 52-week low, attributing it to Middle East conflict, broader market weakness, and potential impact from Trump-era drug pricing policies. Technical indicators like RSI suggest oversold conditions, while dark pool activity indicates uncertainty among institutional investors. The author questions whether the market is overreacting given the company's low P/E ratio and high dividend yield.
Ever since the fighting broke out in the Middle East, the market has been falling for five weeks straight, hasn’t it? My account has been bleeding money, and the S&P 500 seems to be stuck hovering around 6,400 points with no bottom in sight. But what breaks my heart the most is NVO
I still remember how everyone used to rave about it, calling it the gold standard of weight-loss supplements. And now? It’s dropped to $35. It’s really hit its 52-week low. The RSI has even fallen below 26
Is the news about the Trump administration’s most-favored-nation treatment for drug pricing really that devastating? Or is the market overreacting? I see that its P/E ratio is only 10 times right now, and its dividend yield is over 5%.
I noticed a large volume of dark pool trades around the 35.10 price level. It seems that the big players are either holding their ground at this level or preparing to dump their shares en masse once the price breaks below 35.
I'm curious to hear your thoughts. Has the myth of diet pills finally been debunked?